Toggle menu

PREFER

Start date:
Historic
End date:
June 2014
Co-ordinated by:
Daiichi Sankyo Deutschland GmbH, Munich

Prefer in VTE Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism

 

Aim

To assess the 12 month direct health care resource use and estimated costs following acute first-time (initial) or recurrent VTE

Trial Design

Multi –national, multi-centre, prospective observational disease registry

Chief Investigator

Dr Petra Laeis, Munich

Local PI

Dr. Matt Reed

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

More EMERGE Trials

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Attitudes towards Research and Research Nurses among the clinical team in an Emergency Department (ED) and Acute Medical Unit (AMU)

Read more

Research on Research

Attitudes towards Research and Research Nurses

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial